PLGA-Based Nanoparticulate Systems

The therapeutic prospective of drug carrier systems in health care sector is continuously expanding. The uses of various nanocarriers to alter the undesirable features of drugs such as low solubility and reduced permeability in cells have been extensively studied. The distinctive properties associated with nanomaterials result in unique interactions between cells which were previously not reported. Nanoparticles can facilitate as carriers of drugs and protect them from external factors in addition to providing a platform for sustained drug release. Nanoparticulate systems are effective in facilitating intracellular delivery of bioactive materials. PLGA (polylactide-co-glycolide) nanoparticulate systems have been extensively studied as drug carriers, and they are a class of polymers that are biodegradable and approved by the Food and Drug Administration (FDA) for human use. The mechanism of endocytosis of PLGA nanoparticulate systems has been well explored in multiple biological barriers including the respiratory airway, gut, renal proximal tubule, and corneal epithelium. However, the challenges remain to understand the exact process through which molecules can be targeted and how the specific organs can be targeted. Therefore, in this chapter, we have discussed about the concepts of medicinal uses of PLGA nanoparticulate systems and future scope in the treatment of a wide range of disorders.